uric acid has been researched along with Hematologic Neoplasms in 23 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Serum uric acid (sUA) control is of key relevance in tumor lysis syndrome (TLS) prevention as it correlates with both TLS and renal event risk." | 9.20 | FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. ( Aurer, I; Baldini, S; Borsaru, G; Bosi, A; Capriati, A; Federico, M; Glushko, NL; Grosicki, S; Jakucs, J; Jordan, K; Maggi, CA; Mayer, J; Montesinos, P; Nagy, Z; Pristupa, AS; Rego, EM; Ribera, JM; Ristic, D; Scartoni, S; Simonelli, C; Spina, M, 2015) |
| "Rasburicase is effective in controlling plasma uric acid in pediatric patients with hematologic malignancies." | 9.14 | Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. ( Abboud, CN; Brown, A; Cortes, J; Craig, M; Dey, BR; Krishnamurthy, M; Laadem, A; Luger, S; Matous, J; Maziarz, RT; Moore, JO; Pham, D; Schiller, GJ; Seiter, K; Wetzler, M, 2010) |
| "The aim of the present study was to determine if febuxostat could prevent tumor lysis syndrome (TLS) in children who received induction chemotherapy for hematologic malignancies." | 7.85 | Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies. ( Hori, D; Kishimoto, K; Kobayashi, K; Kobayashi, R; Sano, H; Suzuki, D, 2017) |
| "Tumor lysis syndrome (TLS) is a life-threatening oncological emergency, and control of serum uric acid level (S-UA) is most important." | 7.80 | Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study. ( Iwasaki, H; Kishi, S; Matsuda, Y; Nakamura, T; Ookura, M; Tai, K; Takai, M; Ueda, T; Yamauchi, T; Yoshida, A, 2014) |
| "Serum uric acid (sUA) control is of key relevance in tumor lysis syndrome (TLS) prevention as it correlates with both TLS and renal event risk." | 5.20 | FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. ( Aurer, I; Baldini, S; Borsaru, G; Bosi, A; Capriati, A; Federico, M; Glushko, NL; Grosicki, S; Jakucs, J; Jordan, K; Maggi, CA; Mayer, J; Montesinos, P; Nagy, Z; Pristupa, AS; Rego, EM; Ribera, JM; Ristic, D; Scartoni, S; Simonelli, C; Spina, M, 2015) |
| "Rasburicase is effective in controlling plasma uric acid in pediatric patients with hematologic malignancies." | 5.14 | Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. ( Abboud, CN; Brown, A; Cortes, J; Craig, M; Dey, BR; Krishnamurthy, M; Laadem, A; Luger, S; Matous, J; Maziarz, RT; Moore, JO; Pham, D; Schiller, GJ; Seiter, K; Wetzler, M, 2010) |
| "2 mg/kg/day once daily for 3-5 days (twice daily allowed during the first 72 hr) by intravenous route for hyperuricemia (uric acid > 7." | 5.12 | Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea. ( Ahn, HS; Choi, HS; Choi, YM; Chung, NG; Ghim, T; Hwang, TJ; Kang, HJ; Kim, HK; Kim, SY; Koo, HH; Kook, H; Lee, KC; Lee, KS; Lee, MJ; Lee, SM; Lee, WS; Lyu, CJ; Moon, HN; Park, ES; Seo, JJ; Shin, HY; Yoo, KH, 2006) |
| "The aim of the present study was to determine if febuxostat could prevent tumor lysis syndrome (TLS) in children who received induction chemotherapy for hematologic malignancies." | 3.85 | Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies. ( Hori, D; Kishimoto, K; Kobayashi, K; Kobayashi, R; Sano, H; Suzuki, D, 2017) |
| "In order to elucidate the mechanism of hyperuricemia in hematologic malignancies, we have retrospectively investigated the uric acid metabolism in 418 chemotherapy-naïve patients with hematologic malignancies." | 3.80 | Hyperuricemia in hematologic malignancies is caused by an insufficient urinary excretion. ( Akiyama, N; Fujimori, S; Kawasugi, K; Oka, Y; Shirafuji, N; Sirasaki, R; Tashiro, H; Yamamoto, T, 2014) |
| "Tumor lysis syndrome (TLS) is a life-threatening oncological emergency, and control of serum uric acid level (S-UA) is most important." | 3.80 | Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study. ( Iwasaki, H; Kishi, S; Matsuda, Y; Nakamura, T; Ookura, M; Tai, K; Takai, M; Ueda, T; Yamauchi, T; Yoshida, A, 2014) |
| "Rasburicase is indicated for the initial management of plasma uric acid levels in adults receiving anticancer therapy who are at risk for acute tumor lysis syndrome (TLS) and subsequent hyperuricemia." | 3.76 | Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients. ( Shanholtz, CB; Thompson, JL; Vines, AN, 2010) |
| "Twenty-one patients with hematologic malignancies in complete remission undergoing myeloablative peripheral blood HSCT received recombinant urate oxidase at ." | 2.79 | Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation. ( Attar, E; Ballen, K; Brunner, AM; Caron, M; Chen, YB; Coughlin, E; Dey, BR; McAfee, S; Preffer, FI; Spitzer, TR; Yeap, BY; Yeh, AC, 2014) |
| "Allantoin was analyzed as the product of uric acid oxidation." | 1.31 | Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation. ( Berger, HM; Dürken, M; Finckh, B; Fischer, R; Herrnring, C; Kohlschütter, A; Kohlschütter, B; Moison, RM; Nagel, S; Nielsen, P; Pichlmeier, U; Zander, AR, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (34.78) | 29.6817 |
| 2010's | 14 (60.87) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Kawaguchi, S | 1 |
| Fujiwara, SI | 1 |
| Murahashi, R | 1 |
| Nakashima, H | 1 |
| Matsuoka, S | 1 |
| Ikeda, T | 1 |
| Toda, Y | 1 |
| Ito, S | 1 |
| Ban, T | 1 |
| Nagayama, T | 1 |
| Umino, K | 1 |
| Minakata, D | 1 |
| Nakano, H | 1 |
| Yamasaki, R | 1 |
| Ashizawa, M | 1 |
| Yamamoto, C | 1 |
| Hatano, K | 1 |
| Sato, K | 1 |
| Oh, I | 1 |
| Ohmine, K | 1 |
| Kanda, Y | 1 |
| Kishimoto, K | 1 |
| Kobayashi, R | 1 |
| Hori, D | 1 |
| Sano, H | 1 |
| Suzuki, D | 1 |
| Kobayashi, K | 1 |
| Canet, E | 1 |
| Cheminant, M | 1 |
| Zafrani, L | 1 |
| Thieblemont, C | 1 |
| Galicier, L | 1 |
| Lengline, E | 1 |
| Schnell, D | 1 |
| Reuter, D | 1 |
| Darmon, M | 1 |
| Schlemmer, B | 1 |
| Azoulay, E | 1 |
| Yeh, AC | 1 |
| Brunner, AM | 1 |
| Spitzer, TR | 1 |
| Chen, YB | 1 |
| Coughlin, E | 1 |
| McAfee, S | 1 |
| Ballen, K | 1 |
| Attar, E | 1 |
| Caron, M | 1 |
| Preffer, FI | 1 |
| Yeap, BY | 1 |
| Dey, BR | 2 |
| Oka, Y | 1 |
| Tashiro, H | 1 |
| Sirasaki, R | 1 |
| Yamamoto, T | 1 |
| Akiyama, N | 1 |
| Kawasugi, K | 1 |
| Shirafuji, N | 1 |
| Fujimori, S | 1 |
| Jayabose, S | 1 |
| Kumar, V | 1 |
| Dhanabalan, R | 1 |
| Rajan, P | 1 |
| Rathnam, K | 1 |
| Viswanathan, TK | 1 |
| Kuzmina, Z | 1 |
| Gounden, V | 1 |
| Curtis, L | 1 |
| Avila, D | 1 |
| Rnp, TT | 1 |
| Baruffaldi, J | 1 |
| Cowen, EW | 1 |
| Naik, HB | 1 |
| Hasni, SA | 1 |
| Mays, JW | 1 |
| Mitchell, S | 1 |
| Baird, K | 1 |
| Steinberg, SM | 1 |
| Pavletic, SZ | 1 |
| Takai, M | 1 |
| Yamauchi, T | 1 |
| Ookura, M | 1 |
| Matsuda, Y | 1 |
| Tai, K | 1 |
| Kishi, S | 1 |
| Yoshida, A | 1 |
| Iwasaki, H | 1 |
| Nakamura, T | 1 |
| Ueda, T | 1 |
| Spina, M | 1 |
| Nagy, Z | 1 |
| Ribera, JM | 1 |
| Federico, M | 1 |
| Aurer, I | 1 |
| Jordan, K | 1 |
| Borsaru, G | 1 |
| Pristupa, AS | 1 |
| Bosi, A | 1 |
| Grosicki, S | 1 |
| Glushko, NL | 1 |
| Ristic, D | 1 |
| Jakucs, J | 1 |
| Montesinos, P | 1 |
| Mayer, J | 1 |
| Rego, EM | 1 |
| Baldini, S | 1 |
| Scartoni, S | 1 |
| Capriati, A | 1 |
| Maggi, CA | 1 |
| Simonelli, C | 1 |
| Dupré, A | 1 |
| Mousseaux, C | 1 |
| Bouguerba, A | 1 |
| Ayed, S | 1 |
| Barchazs, J | 1 |
| Boukari, M | 1 |
| Goldgran-Toledano, D | 1 |
| Bornstain, C | 1 |
| Vincent, F | 1 |
| Kikuchi, A | 1 |
| Kigasawa, H | 1 |
| Tsurusawa, M | 1 |
| Kawa, K | 1 |
| Kikuta, A | 1 |
| Tsuchida, M | 1 |
| Nagatoshi, Y | 1 |
| Asami, K | 1 |
| Horibe, K | 1 |
| Makimoto, A | 1 |
| Tsukimoto, I | 1 |
| Giraldez, M | 1 |
| Puto, K | 1 |
| Cortes, J | 1 |
| Moore, JO | 1 |
| Maziarz, RT | 1 |
| Wetzler, M | 1 |
| Craig, M | 1 |
| Matous, J | 1 |
| Luger, S | 1 |
| Schiller, GJ | 1 |
| Pham, D | 1 |
| Abboud, CN | 1 |
| Krishnamurthy, M | 1 |
| Brown, A | 1 |
| Laadem, A | 1 |
| Seiter, K | 1 |
| Trifilio, SM | 1 |
| Pi, J | 1 |
| Zook, J | 1 |
| Golf, M | 1 |
| Coyle, K | 1 |
| Greenberg, D | 1 |
| Newman, D | 1 |
| Koslosky, M | 1 |
| Mehta, J | 1 |
| Vines, AN | 1 |
| Shanholtz, CB | 1 |
| Thompson, JL | 1 |
| Malaguarnera, G | 1 |
| Giordano, M | 1 |
| Malaguarnera, M | 1 |
| Inai, K | 1 |
| Tsutani, H | 1 |
| Bairaktari, ET | 1 |
| Kakafika, AI | 1 |
| Pritsivelis, N | 1 |
| Hatzidimou, KG | 1 |
| Tsianos, EV | 1 |
| Seferiadis, KI | 1 |
| Elisaf, MS | 1 |
| Shin, HY | 1 |
| Kang, HJ | 1 |
| Park, ES | 1 |
| Choi, HS | 1 |
| Ahn, HS | 1 |
| Kim, SY | 2 |
| Chung, NG | 1 |
| Kim, HK | 1 |
| Kook, H | 1 |
| Hwang, TJ | 1 |
| Lee, KC | 1 |
| Lee, SM | 1 |
| Lee, KS | 1 |
| Yoo, KH | 1 |
| Koo, HH | 1 |
| Lee, MJ | 1 |
| Seo, JJ | 1 |
| Moon, HN | 1 |
| Ghim, T | 1 |
| Lyu, CJ | 1 |
| Lee, WS | 1 |
| Choi, YM | 1 |
| Wang, LY | 1 |
| Shih, LY | 1 |
| Chang, H | 1 |
| Jou, ST | 1 |
| Lin, KH | 1 |
| Yeh, TC | 1 |
| Lin, SF | 1 |
| Liang, DC | 1 |
| Hochberg, J | 1 |
| Cairo, MS | 1 |
| Dürken, M | 1 |
| Herrnring, C | 1 |
| Finckh, B | 1 |
| Nagel, S | 1 |
| Nielsen, P | 1 |
| Fischer, R | 1 |
| Berger, HM | 1 |
| Moison, RM | 1 |
| Pichlmeier, U | 1 |
| Kohlschütter, B | 1 |
| Zander, AR | 1 |
| Kohlschütter, A | 1 |
| Pui, CH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rasburicase to Prevent Graft -Versus-Host Disease[NCT00513474] | Phase 1 | 46 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies: a Randomized, Double Blind, Phase III Study Versus Allopurinol[NCT01724528] | Phase 3 | 346 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. (NCT00513474)
Timeframe: Up to 71 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rasburicase Group | 21 |
| Control Group | 21 |
"aGVHD severity was determined using International Bone Marrow Transplant Registry (IBMTR) scale stage and grade of the skin, liver and gut. Stage 1: Skin=maculopapular rash <25% of body surface; Liver=Bilirubin 2-3 mg/dL and Gut=500-999 mL diarrhea/day or peristent nausea with histologic evidence of GvHD. Stage 2: Skin=maculopapular rash 25-50% of body surface; Liver=Bilirubin 3.1-6 mg/dL and Gut=1000-1499 mL diarrhea/day. Stage 3: Skin=maculopapular rash >50% of body surface; Liver=Bilirubin 6.1-15 mg/dL and Gut=≥1500 mL diarrhea/day. Stage 4: Skin=generalized erythroderma with bulla formation; Liver=Bilirubin >15 mg/dL and Gut=severe abdominal pain.~Grade 1: Stage 1-2 rash; no liver or gut involvement. Grade II: Stage 3 rash, or stage 1 liver involvement, or stage 1 gut involvement. Grade III: None to stage 3 skin rash with stage 2-3 liver, or stage 2-4 gut involvement. Grade IV: Stage 4 skin rash, or stage 4 liver involvement." (NCT00513474)
Timeframe: Up to 71 months
| Intervention | percentage of participants (Number) |
|---|---|
| Rasburicase Group | 24 |
| Control Group | 57 |
Blood was collected and analyzed at a laboratory for serum uric acid levels reported in milligrams(mg)/deciliter(dL). Data is presented for those participants who experienced Grade II to IV aGVHD and those participants who did not experience Grade II to IV aGVHD at pre-transplant and post-transplant. (NCT00513474)
Timeframe: Pre-transplant Day -7 to Day -1 and Post-transplant Day 0 to Day 6
| Intervention | mg/dL (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day -7 | Day -6 | Day -5 | Day -4 | Day -3 | Day -2 | Day -1 | Day 0 | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | |
| Control Group | 4.157 | 3.419 | 2.967 | 2.579 | 2.358 | 1.867 | 1.71 | 2.163 | 2.671 | 2.778 | 2.805 | 2.758 | 2.579 | 2.653 |
| Rasburicase Group | 0.1 | 0.075 | 0.086 | 0.1 | 0.067 | 0.081 | 0.438 | 0.938 | 1.624 | 2.076 | 2.271 | 2.548 | 2.595 | 2.705 |
Assessment of CTLS, from Day 3 to Day 8. According to Cairo-Bishop definition, CTLS is defined by the presence of LTLS in addition to 1 or more of the following significant clinical complications: renal insufficiency, cardiac arrhythmias, sudden death and seizures. The grade of CTLS is defined by the maximal grade of the clinical manifestation (NCT01724528)
Timeframe: 6 days
| Intervention | % of patients with CTLS occurrence (Number) |
|---|---|
| Febuxostat | 1.7 |
| Allopurinol | 1.2 |
Assessment of LTLS, from Day 3 to Day 8. According to Cairo-Bishop definition LTLS is defined by the presence of 2 or more laboratory abnormalities including: a 25% increase or levels above normal for serum uric acid, potassium, and phosphate or a 25% decrease or levels below normal for calcium. (NCT01724528)
Timeframe: 6 days
| Intervention | % of patients with LTLS occurrence (Number) |
|---|---|
| Febuxostat | 8.1 |
| Allopurinol | 9.2 |
Change in serum creatinine level from baseline (Day 1) to the evaluation visit (Day 8) (NCT01724528)
Timeframe: 8 days
| Intervention | change % (Mean) |
|---|---|
| Febuxostat | -0.83 |
| Allopurinol | -4.92 |
Area under the curve of sUA from baseline (Day 1) to the evaluation visit (Day 8) (NCT01724528)
Timeframe: 8 days
| Intervention | mg x hour/dL (Mean) |
|---|---|
| Febuxostat | 514.0 |
| Allopurinol | 708.0 |
Assessment of treatment responder rate, where treatment response is defined as the maintenance of sUA ≤ 7.5 mg/dL from Day 3 to Day 8 (NCT01724528)
Timeframe: 6 days
| Intervention | % of patients who fail to respond (Number) |
|---|---|
| Febuxostat | 1.7 |
| Allopurinol | 4.0 |
2 reviews available for uric acid and Hematologic Neoplasms
| Article | Year |
|---|---|
Rasburicase for the treatment of tumor lysis in hematological malignancies.
Topics: Hematologic Neoplasms; Humans; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid | 2012 |
[Secondary hyperuricemia in hematologic disease].
Topics: Allopurinol; Enzyme Inhibitors; Hematologic Neoplasms; Humans; Hyperuricemia; Urate Oxidase; Uric Ac | 2003 |
7 trials available for uric acid and Hematologic Neoplasms
| Article | Year |
|---|---|
Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation.
Topics: Acute Disease; Adult; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neopl | 2014 |
Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antineoplastic Agents | 2015 |
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Febuxostat; Female; Follow-Up Stud | 2015 |
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Febuxostat; Female; Follow-Up Stud | 2015 |
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Febuxostat; Female; Follow-Up Stud | 2015 |
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Febuxostat; Female; Follow-Up Stud | 2015 |
A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Hypersensi | 2009 |
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Antineoplastic Agents | 2010 |
Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea.
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Female; Hematologic Neoplasms; Hu | 2006 |
Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Calcium; Child; Child, Preschool; Female; Hematologic Ne | 2006 |
14 other studies available for uric acid and Hematologic Neoplasms
| Article | Year |
|---|---|
Risk factors for high-dose methotrexate-induced nephrotoxicity.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Female; Hematologic Neoplasms; Humans; Kid | 2021 |
Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies.
Topics: Adolescent; Age Factors; Allopurinol; Antineoplastic Agents; Biomarkers; Child; Child, Preschool; Cr | 2017 |
Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?
Topics: Acute Kidney Injury; Adult; Aged; Biomarkers; Female; Follow-Up Studies; Hematologic Neoplasms; Huma | 2014 |
Hyperuricemia in hematologic malignancies is caused by an insufficient urinary excretion.
Topics: Aged; Female; Hematologic Neoplasms; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Retrospective | 2014 |
Low-dose rasburicase in hematologic malignancies.
Topics: Adolescent; Child; Child, Preschool; Female; Gout Suppressants; Hematologic Neoplasms; Humans; India | 2015 |
Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
Topics: Aged; Allopurinol; Antineoplastic Agents; Creatinine; Enzyme Inhibitors; Febuxostat; Female; Glomeru | 2014 |
[Analysis of the 2015 British guidelines on the prevention and management of tumor lysis syndrome].
Topics: Adult; Allopurinol; Child; Hematologic Neoplasms; Humans; Incidence; Neoplasms; Practice Guidelines | 2017 |
A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults.
Topics: Adolescent; Adult; Hematologic Neoplasms; Humans; Male; Retrospective Studies; Treatment Outcome; Tu | 2010 |
Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies.
Topics: Adult; Aged; Aged, 80 and over; Gout Suppressants; Hematologic Neoplasms; Humans; Hyperuricemia; Mid | 2011 |
Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Creatinine; Dose-Response Relationship, Drug; Drug Administration Sc | 2010 |
Hypouricemia in individuals admitted to an inpatient hospital-based facility.
Topics: Blood Glucose; Diabetes Mellitus; Glycosuria; Hematologic Neoplasms; Hospital Departments; Humans; I | 2003 |
Tumor lysis syndrome: current perspective.
Topics: Allopurinol; Area Under Curve; Hematologic Neoplasms; Humans; Medical Oncology; Models, Biological; | 2008 |
Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation.
Topics: Allantoin; Antineoplastic Agents; Antioxidants; Bone Marrow Transplantation; Busulfan; Combined Moda | 2000 |
Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.
Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Child; Clinical T | 2001 |